Sacubitril/valsartan inhibits both angiotensin receptors and neprilysin and it is more efficient than enalapril in decreasing the risk of worsening of HF, the need for more intensive treatment, or heart transplantation in patients with HF with reduced ejection fraction (HFrEF) [91]. Here, MME is linked to hydrops fetalis.